Abcam developed a new analytical antibody for Merck KGaA

| By | Cancer Drugs, Drug Development, Merck KGaA

Abcam, a global innovator in life science reagents and tools, announced the commercial launch of the new anti-PD-L1 antibody clone MKP1A07310 (clone 73-10) developed in collaboration with Merck KGaA (Darmstadt, Germany).

Developed by Abcam for use by Merck as an analytical antibody to support Merck’s therapeutic programme several years ago, this new clone has been created by Abcam’s in-house antibody engineers, who specialise in the discovery and development of challenging antibodies. The antibody is important in assessing the expression of PD-L1 in tumors from patients who might be able to benefit from PD-1/PD-L1 checkpoint immunotherapy.

Abcam, headquartered in Cambridge (UK), is a life-science e-commerce company which facilitates public customer feedback on products using reviews and ratings submitted by customers. Since 2011, through acquisition, the company has moved into direct production of biotechnological products. Abcam produces and distributes high quality research-grade antibodies and associated proteomics research products. The company has eleven locations in the world’s leading life science research hubs.

Merck KGaA (Darmstadt, Germany) is a leading science and technology company in healthcare, life science and performance materials.

SOURCE: abcam
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.